Identification of Anti-Long Chain Saturated Fatty Acid IgG Antibodies in Serum of Patients with Type 2 Diabetes
Table 4
Study participant clinical characteristics with complete datasets at baseline and 3 months, . Values are presented as the mean ± SD.
Variables
Baseline
3 months
Mean difference
value
Anti-LCSFAlmitic acid IgG (corrected OD)
0.79 ± 0.40
0.17 ± 0.09
0.71 ± 0.44
0.001
IL-1β (pg/mL)
1.09 ± 0.46
0.98 ± 0.38
0.100 ± 0.44
0.442
Fasting glucose (mg/dL)
153.77 ± 65.12
143.62 ± 61.95
10.15 ± 19.36
0.050
HbA1c (%)
7.7 ± 2.2
6.8 ± 1.4
0.9 ± 1.2
0.005
HbA1c (mmol/mol)
61 ± 24
50 ± 15
11 ± 13
0.005
Insulin (pmol/L)
90.48 ± 74.88
99.30 ± 115.68
−8.88 ± 64.74
1.00
Cholesterol (mg/dL)
170.23 ± 33.51
158.54 ± 38.40
11.69 ± 31.60
0.184
HDL cholesterol (mg/dL)
45.00 ± 8.19
48.00 ± 7.916
−3.00 ± 4.43
0.049
LDL cholesterol (mg/dL)
98.62 ± 25.92
93.15 ± 25.35
5.46 ± 21.89
0.382
Cholesterol/HDL ratio (%)
3.86 ± 0.85
3.35 ± 0.67
0.50 ± 0.63
0.023
Triglycerides (mg/dL)
249.38 ± 174.09
191.92 ± 36.15
57.46 ± 98.02
0.075
TANITA fat mass (kg)
36.15 ± 12.40
33.98 ± 11.63
2.16 ± 2.45
0.013
TANITA fat percent (%)
42.25 ± 7.27
40.56 ± 7.43
1.66 ± 1.97
0.034
Scale weight (kg)
83.74 ± 16.10
82.17 ± 15.38
1.56 ± 3.20
0.100
Waist circumference (cm)
101.43 ± 9.73
99.89 ± 10.33
1.54 ± 5.36
0.196
Hip circumference (cm)
111.05 ± 13.91
111.94 ± 12.76
−0.89 ± 3.82
0.294
BMI (kg/m2)
32.33 ± 6.33
32.11 ± 5.54
0.22 ± 2.64
0.039
DXA-trunk fat (kg)
16.60 ± 43.79
15.66 ± 41.20
0.94 ± 1.06
0.007
DXA-trunk percent fat (%)
37.55 ± 6.78
36.36 ± 6.49
1.18 ± 1.68
0.041
DXA-total fat (kg)
31.81 ± 11.06
30.27 ± 10.21
1.53 ± 1.86
0.013
DXA-total percent fat (%)
36.94 ± 8.11
35.90 ± 7.85
1.04 ± 1.18
0.012
Optical density. A brand of bioelectric impendence technology which measures body composition. TANITA scales measure within 5% of DXA. DXA: dual-energy X-ray absorptiometry.
